M+QuickMedCalc
Educational reference only. Not a diagnostic tool. See full disclaimer.
Emergency Medicine & Critical CareBova Score

Bova Score Calculator for Pulmonary Embolism

Calculate original Bova points and stage in normotensive confirmed acute PE from systolic pressure, heart rate, assay-classified troponin and documented RV dysfunction.

Content updated: View sources

QuickMedCalc is developed and maintained by an independent developer. Medical content is not independently reviewed by a physician.

Formula and medical content are based on the references listed on this page. See sources, About, and Sources and Review Process.

Original Bova for normotensive confirmed acute PE. Enter observed values and externally assessed biomarker/imaging findings. [1, 3]

Bova was developed for normotensive confirmed acute PE. Persistent hypotension, shock or cardiopulmonary failure requires a separate pathway. Hemodynamic deterioration overrides a static score; do not delay care for an online calculation.

About

The Bova score calculator applies the original 2014 seven-point index after acute symptomatic pulmonary embolism is confirmed and the normotensive assessment context is established. It estimates source-defined risk strata for 30-day PE-related complications: PE-related death, hemodynamic collapse or recurrent PE. It is not a diagnostic rule, an all-cause-mortality-only model, or an outpatient eligibility test. The development analysis pooled 2,874 normotensive patients from six prospective PE studies. [1]

Only four predictors contribute: systolic pressure 90–100 mmHg (+2), elevated cardiac troponin (+2), documented RV dysfunction (+2), and heart rate ≥110 beats/min (+1). This is not modified Bova, lactate-augmented Bova, FAST, TELOS or CPES. [1, 3]

Formula

Bova = SBP points + troponin points + RV dysfunction points + heart-rate points (0–7).
SBP 90–100 inclusive: +2; elevated troponin: +2; RV dysfunction: +2; HR ≥110: +1. SBP <90: no score.

Interpretation

Original stage and current-guideline component are separate

Bova totalOriginal 2014 stage2026 AHA/ACC clinical-severity score component
0–2Stage ILow
3–4Stage IILow
5–7Stage IIIElevated

Stage II is not “AHA elevated”: totals 3–4 remain Stage II in the original Bova model and Low in the separate 2026 severity-score component. Bova alone does not determine AHA/ACC category A–E, C1–C3 or a respiratory R modifier. [1, 3]

Historical 2014 cohort outcomes

These are historical cohort observations, not your complication probability or an individual mortality estimate. The complication composite is PE-related death, hemodynamic collapse or recurrent PE; time windows and endpoints must not be mixed. [1]

Stage30-day PE-related complicationsIn-hospital PE-related complications30-day PE-related mortality
I4.2%3.6%1.7%
II10.8%9.7%5.0%
III29.2%28.0%15.5%

Prospective validation: rates vary across cohorts

The 2018 prospective validation enrolled 639 consecutive normotensive acute-PE patients. Its 30-day composite of PE-related mortality, hemodynamic collapse and nonfatal PE recurrence occurred in 7.0% overall: Stage I 2.9%, Stage II 17%, Stage III 27%. All-cause mortality was 5.3% and did not substantially differ by stage. These outcomes are not merged with the 2014 data into a synthetic probability. [2]

Troponin and RV imaging evidence

The pooled model uses binary elevated cardiac troponin and RV dysfunction assessed by echocardiography or CT. Cohort assays, reference thresholds and operational imaging definitions differ. Use the externally established classifications from this assessment; there is no universal numeric troponin or RV/LV threshold added here. Missing testing is not a negative result. [1]

Current guidance supports structured RV assessment, but that does not replace the original Bova binary predictor with a new imaging calculator. The 2026 guideline has a separate correction; no Bova scoring change is attributed to that correction. [3, 4]

Current 2026 AHA/ACC limits

Table 6 retains the four Bova weights and original stages. The current clinical-category framework uses Bova ≤4 as an example of a Low clinical-severity score and >4 as Elevated. The full categories additionally require clinical, hemodynamic, laboratory, imaging and respiratory information. Hypotension, cardiopulmonary failure, normotensive shock or hypoperfusion, MAP, lactate, AKI/urine output and cardiac index are not all captured by Bova. A low total cannot override deterioration. [3]

No stage mandates thrombolysis or another intervention. This calculator does not choose a medicine, dose, monitoring interval, admission, discharge or home treatment. Do not delay clinical care to complete it.

Bova vs PESI, NEWS2 and other PE tools

PESI/sPESI use broader clinical variables for short-term, principally all-cause-mortality-oriented prognosis after confirmed PE. Bova focuses on PE-related complications within its normotensive source population and uses cardiac biomarker/RV imaging evidence; the models can disagree and are not interchangeable. NEWS2 measures general physiological deterioration rather than this PE-specific endpoint. [1, 3]

Wells PE concerns suspected-PE pretest probability, PERC is conditional rule-out, and YEARS combines suspected-PE criteria with D-dimer. Hestia is a separate outpatient eligibility/exclusion framework. CPES is a separate 0–6 model incorporating troponin, BNP, RV function, central thrombus burden, concomitant DVT and HR ≥100. None is calculated or converted from Bova here. [3]

References

  1. Bova C, Sanchez O, Prandoni P, et al. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. Eur Respir J. 2014;44(3):694–703. PMID 24696111. DOI 10.1183/09031936.00006114.
  2. Bova C, Vanni S, Prandoni P, et al. A prospective validation of the Bova score in normotensive patients with acute pulmonary embolism. Thromb Res. 2018;165:107–111. PMID 29631073. DOI 10.1016/j.thromres.2018.04.002.
  3. Creager MA, Barnes GD, Giri J, et al. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults. Circulation. 2026;153:e977–e1051. PMID 41712677. DOI 10.1161/CIR.0000000000001415.
  4. Creager MA, Barnes GD, Giri J, et al. Correction to the 2026 Acute Pulmonary Embolism Guideline. Circulation. 2026;154(2):e24. PMID 42441758. DOI 10.1161/CIR.0000000000001462.

FAQ

Related Calculators

Disclaimer

Educational and informational reference only. Not intended to replace professional medical advice, diagnosis, treatment, or independent verification.